Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Connecticut Daily Journal.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on June 6, 2025
Paramount Wellness Retreat Addresses the Link Between ADHD and Addiction with Specialized Dual Diagnosis Treatment
EIN Presswire
·
June 6, 2025
Comprehensive Care for ADHD and Co-Occurring Substance Use Disorders HADDAM, CT, UNITED STATES, June 6, 2025 /EINPresswire.com/ -- Attention Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental condition that often persists into …
Leverage Shares by Themes continues product expansion with a first-to-market new single stock Leveraged ETF, bringing investors an exciting opportunity to amplify exposure to RTX Corporation (RTX)
GlobeNewswire
·
June 6, 2025
GREENWICH, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Leverage Shares by Themes, an issuer of innovative exchange-traded products, is excited to announce the launch of a first-to-market new single stock leveraged ETF, available for trading starting June 6, …
FuelCell Energy Reports Second Quarter of Fiscal 2025 Results
GlobeNewswire
·
June 6, 2025
Second Quarter Fiscal 2025 Summary (All comparisons are year-over-year unless otherwise noted) Revenue of $37.4 million, compared to $22.4 million, an increase of approximately 67% Gross loss of $(9.4) million compared to $(7.1) million, an increase of …
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire
·
June 6, 2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 …